Molecular Sensing, Inc. is launching a breakthrough molecular interaction technology for drug discovery.
Back-Scattering Interferometry (BSI) enables:
Label-free, in solution Kd measurements eliminating both immobilization and target molecule labeling.
Unprecedented sensitivity and Kd dynamic range for small molecule — large protein binding compared to SPR and ITC.
Analyze binding equilibrium Kd's from pM to mM in complex matrices — serum, DMSO, cell lysates, impure mixtures and cell membrane preparations.
Use of small quantities (nanomoles) and volumes (10 µL) of protein radically reducing target protein development and manufacturing cost.
MSI is currently working toward commercial launch of the first BSI instrument for drug discovery and biotherapeutic research. Immediate access to the technology is available through a service based Life-science Early Access Program (LEAP).
Please contact us if you have a critical need to improve:
Biophysical profiling of drug candidate
Lead optimization assay
Medicinal chemistry drug optimization
Label free assays
Measurement of pM to mM Kd's
Binding studies in impure mixtures
Characterize binding under native
Assess promiscuous binders
Reduce protein target quantities
Correlation of cell-based assays
to target binding assays